Responses to frequently asked questions regarding the purpose of shareholder meeting

The following is correspondence between the CEO and two of our shareholders which we believe is informative on the Company’s perspective on ballot initiatives for the upcoming shareholder meeting.

Gary,

Thank you for your input and support.

I just responded to another shareholder’s inquiry and am including my response to him below, as some of his concerns overlap yours and I think are representative of questions and input I have received from a few others.

On the question of the preferred stock, I think your concerns have some merit.  Super majorities do have a mixed history.  My intention when I received the preferred back in 2013 was to make sure that we always had the votes necessary to execute on our business plan.  The thinking at that time was that if there was an opportunity for a significant acquisition, merger or up-list, time would be of the essence.  The corporate charter was amended at that time to allow a majority to take such action without a shareholder meeting.  The reason was that it takes significant planing, delays and expense to hold a shareholder meeting and a significant opportunity could slip through our hands in that time.

It is a bit ironic then that, now, when we have a possible opportunity for an up-list, we are never the less holding a meeting of shareholders.  

My small team is fully taxed preparing for the meeting while keeping everything else afloat and executing on our plans for Vietnam.  It is fair to say that I am over-taxed as well.  I will keep an open mind about the super majority and seek input from the team and our securities counsel in the coming weeks and months.

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.


Zach,

Thank you for your email.  I am responding to you directly because it looks like you have done your homework on the history of RS.

I do not doubt the Stern data.  Typically when a company does a RS it is because the stock price has been eroding over time and the company can not maintain its exchange listing at the new stock price.  While I have not seen any data, it may also be the case that companies enter into a RS because of covenants on their debt interments or under presser from debt holders. Of course such companies have a tendency to under perform.  They have a history of under-performance.

For Kraig Labs, that is simply not the case.  Our stock has shown significant historical gains (even accounting for the recent pull back) and we are hitting the major milestones we have set for ourselves in terms of setting up production and early stage commercialization.  It is that growth which has given us a possible path to a national exchange.

Historically, we have run this Company on very thin financing.  Now that we need to ramp up production, thin financing will not allow us to ramp up quickly enough to meet our targets or to satisfy the potential customers that we are talking with.

I can not predict the stock price.  I do not know where it is going any more than anyone else.  But I do have strong opinions about what it will take to make the Company a success and what it will take to bring our products to market in a manner that will allow us to beat the competition and capture market share.  My philosophy has always been to focus on the Company’s fundamentals and executing on our business plan.  I do believe that focusing on growing the Company will ultimately benefit our shareholders.

My suggestion would be, that the Stern School data is not as relevant as another set of data.  What happens, statistically, to share price and long term shareholder value when an OTC Company up-lists? 

Our immediate plan to to shoot for the up-list.  There is no guarantee that we will make the up-list.  As I see it we have a relatively small window in which to do this and several moving pieces which need to all move through the window at the same time.  To be frank, my stress levels in engineering and managing this process are very high.  Surprisingly, this is because I think we might just achieve this success and hit the remaining marks in our business plan over the near and medium term.  Some times success itself can be a stresser.  I think the market feels it too.

I know the recent drop in share price is also stressing you and others.  I am personalty affected as well.  But I see opportunity and the possibility of growing this small boat into a bigger and stronger ship.  I chose growth. While I am stressed, I am also excited and, I must confess, elated.

Thank you for your support and your input.  If you chose not to take this ride and see these opportunities through with us I understand.  There are risks, which I do not want to minimize.  It is no my role, as I see it, to convince people to buy the stock or to maintain their investment.  My role it to grow the Company and put in place a strategic vision for market dominance. 

One of the most frustrating aspects of my work is the added burden of being a penny stock and OTC company.  In essence, companies that have made the jump to a national exchange have received at some level a review and participation by investment banks and their client institutions.  Companies which have not gone through that process are always suspect from the perspective of Wall Street and other constituents.  That translates directly to higher costs and closed doors.  If the Company is going to show exponential growth, which is an essential part of our business plan, we need to kick open those doors.  

We are arming ourselves with a battering ram.  I intend to knock on those doors till the hinges come off and the path for our growth is wide open.

Good luck and good fortune to you and for all of us.  

Kim

Kim Thompson, CEO

Kraig Biocraft Laboratories, Inc.

This entry was posted on by .

Kraig Labs Issues Letter to Shareholders in Advance of Annual Meeting

July 14th Letter to Shareholders in preparation for the Annual meeting

Dear Kraig Labs Family,

Last week we shared the news of the Company’s upcoming annual shareholder meeting to be held on July 24th.  We have now completed the mailing of those notices, they should be arriving shortly.  We have also made the notice and proxy voting card available on the Company website at www.kraiglabs.com/shareholder-meetingIf you do not receive a direct mailed notice it may be because your stock is held by a brokerage firm that received the notice.  Please don’t worry, as you can still print and mail in the proxy card from the Company website to have your vote counted.  We encourage all of our shareholders, who owned shares as of the record date, June 12, 2019, to complete and return their proxy voting card, regardless of whether you plan to attend the meeting in person or not.

As we look forward to the upcoming meeting and continue to work towards positioning the Company for the next stage of growth, we thought it appropriate to reflect on recently achieved major accomplishments and to share our immediate goals for our growth and expansion of our operations.

In the last 24 months the Company has transformed itself from a small R&D focused group to a company that management believes is on the verge of becoming the global supplier of spider silk materials.  In this time we have:

  • Established Prodigy Textiles Ltd., our wholly owned Vietnamese subsidiary, which has been granted authorization and business licenses to open recombinant spider silk production operations.
  • Signed a development agreement with a market leader in high performance textiles, to create the next generation of non-woven protective fabrics using spider silk.
  • Secured a factory in Vietnam, to produce our recombinant spider silk, and signed agreements with suppliers and service providers to support growth.
  • Produced the first sample of woven Dragon Silk fabric.
  • Successfully completed a first of its kind, international shipment of transgenic silkworms.
  • Established and staffed the Company’s first standalone R&D headquarters.
  • Created new transgenics with the potential to surpass our existing technologies.
  • Implemented new processes rapidly accelerating the pace of new transgenic development.
  • Expanded our intellectual property position with additional provisional patent filings.
  • Implemented new production quality control systems in preparation for rapid expansion.

With all of these achievements secured, the Company now looks to the future and how best to serve our shareholders, and meet the market demand for our remarkable products.  The expansion of our production operations will require capital, but we must be judicious in how we raise these funds. 

On the financial front, the Company has operated for over 10 years in the “Over The Counter” market (OTC) and managed to prosper, despite the OTC’s significant limitations.  Operating as an OTC company has limited our ability to raise capital from institutional investors, most of whom are prohibited by law, or charter, from investing in penny stock, or OTC companies. 

In the past, we have faced significantly high costs for capital raised.  We have been prevented from using more efficient and cost effective financing tools, which are available to firms listed on the national exchanges.  Unlike many companies who flounder on the OTC, Kraig Labs has managed to survive by being judicious in how we have raised capital, a process that has forced us to limit growth and which has slowed our progress toward commercialization.

The shareholders of Kraig Labs have also faced challenges relating to our penny stock and OTC status. Many brokerage firms will not accept penny stocks and are prohibited from informing their clients about penny stock opportunities.

It is with this experience that we now believe the time has come to consider the possibility of raising the Company to a national exchange and freeing ourselves of the burden of being a penny stock.  This move would provide access to institutional investment not currently available. Moving to a national exchange would lower the cost in raising the capital necessary to finance our growth.  The move would also be designed to provide greater liquidity for our shareholders.  The Board of Directors and management of Kraig Labs are committed to seeing our Company grow and we believe that the best path for this growth is to strengthen and reinforce our position as a publicly traded and publicly owned company by transitioning to a national exchange.

When the Company operated primarily as a small R&D operation, the burdens of being an OTC company were manageable, but, as we now move to commercialize our products and realize the potential of our technology, the time has come to start the next chapter by listing on a national exchange, a move that we believe will benefit the Company, all of our valued shareholders, and the global textile market.

The Company’s work to expand our corporate board, improve our financials, and strengthen corporate governance, including this shareholder meeting, have been a structured and methodical plan to meet the listing requirements for a national exchange, which include share price requirements.  During the upcoming annual meeting we are bringing this vision to all of you, the Company’s stakeholders, to vote on this strategy to unlock the potential of our Company and power of our technology.  We believe these moves will be a great benefit to our shareholders and our ability to capture a share of the global textile market.

After many years of measured and prudent moves, now is the right time for Kraig Labs to accelerate the next steps of our business model roll out and start the next chapter together.

Your voice and your vote are important; we encourage everyone to review all of the materials in the shareholder notice and to submit your proxy voting cards ahead of the annual meeting.  Our recent growth, over the last 12 months, has created a possible opportunity to uplist.  Let us move together and seize that opportunity.  

Thank you for your ongoing support, and good luck to all of us as we move boldly into the future.

Kim Thompson

CEO

Kraig Biocraft Laboratories, Inc.

This entry was posted on by .

Kraig Biocraft Laboratories awarded expanded investment license in Vietnam

ANN ARBOR, Mich., – July 11, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company has been awarded an increased investment license for expansion of its recombinant spider silk production at Prodigy Textiles, its Vietnamese subsidiary. 

Under the new license, the Vietnamese government increased the Company’s potential investment cap, to as high as $50 million USD.  This significantly increased investment limit will now allow the Company to prepare for the second phase expansion, planned for a 123 acre site located near Prodigy Textiles’ existing facility, and is part of the Company’s systematic and structured plan to expand capacity.

This new license was awarded during a recent trip to Vietnam, taken by the Company’s COO, Jon Rice, to oversee phase one production implementation. After reviewing the progress made under this first phase and meeting with Prodigy Textiles’ president, Vietnamese officials authorized the expansion of the Company investment in scaling up recombinant spider silk production.

“The granting of this expanded license is a demonstration of confidence in Kraig Labs and the potential our eco-friendly spider silk technology has to dramatically alter the global markets for silk and performance textiles,” said Rice. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories to host annual shareholder meeting

ANN ARBOR, Mich., – July 8, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that the Company will be holding its 2019 annual shareholder meeting on Wednesday, July 24, at 10 a.m. EDT, at the East Lansing Marriott at University place, located at 300 M.A.C. Ave, East Lansing, MI 48823.  The proxy statement containing the meeting details is expected to be mailed no later than July 13 to shareholders of record as of June 12, 2019.

The shareholder meeting is an important step in positioning the Company to advance its business model, including the growth of its spider silk manufacturing operations. 

Shareholders of record of Kraig Labs common stock and preferred stock, as the close of business on June 12, 2019, are entitle to notice of, and to vote at, the meeting.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.  More information on the shareholder meeting will be posted on the Company’s website in the next few days. 

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories Management Travels to Vietnam to Oversee Prodigy Textiles Construction and Expansion

ANN ARBOR, Mich., – June 11, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that a senior member of its leadership team is travelling to Vietnam to oversee operations at the Company’s subsidiary Prodigy Textiles Ltd., construction at the Company’s new facility, and to coordinate the transfer of silkworms from the temporary facility into their permanent home.  Management also anticipates meeting with provincial leaders to discuss further expansion of Prodigy Textiles production.

During this trip, a senior official from Kraig Labs plans to interview and select candidates for several key positions, including operational and financial leadership roles within Prodigy Textiles.  Management has also set aside time to meet with its Vietnamese bankers to outline and discuss a collaborative agreement as Prodigy Textiles prepares to grow rapidly. 

“Work at Prodigy Textiles has been moving quickly as we have continued to direct progress from our U.S. operations.  It is now time for the Company to send someone back to Vietnam in order to oversee the hiring and filling of key positions as we build out our operational leadership team at Prodigy and transition to larger scale silk production,” said COO, Jon Rice.  “I am excited to watch our international team grow as we work together bringing our environmentally sustainable, high performance textiles and yarns to the global markets.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories promotes Dr. Trevor Kane to Chief Scientist

Kraig Labs R&D Team continues to deliver outstanding breakthroughs

ANN ARBOR, Mich., – June 4, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that, in recognition of the magnitude of multiple recent achievements, Dr. Trevor Kane has been promoted to the position of Chief Scientist. 

His successes in creating new transgenics in the lab and expanding our intellectual property portfolio with several new provisional patent applications mark a significant milestone and advancement in Kraig Labs mission to produce and commercialize eco-friendly materials that exceed the performance and strength of native spider silk. 

“These new powerful transgenics, recently created by Dr. Kane’s team, were designed for broad commercial appeal. Dr. Kane has certainly earned his promotion with the successful development of this new architecture. This next generation technology, developed in our labs, has the potential to radically advance gains in material performance, above and beyond anything we’ve previously produced,” said CEO and Founder, Kim Thompson.

“I would like congratulate and commend Dr. Kane and our entire R&D team for their success in developing these breakthrough technologies,” said COO Jon Rice.

These new transgenics incorporate several technologies covered by the Company’s recent provisional patent applications and set the stage for new commercial applications. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Spider Silk Production Breakthrough from Kraig Biocraft Laboratories

Innovation from Kraig Labs R&D Team delivers next generation Spider Silk

ANN ARBOR, Mich., – May 30, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today the creation of the next generation of recombinant spider silk using the Company’s new design, gene editing, and incorporation approaches. Kraig Labs designed this approach to customize mechanical properties for specific commercial markets and has demonstrated the ability to more quickly, accurately, and efficiently, generate new transgenics. 

This is the material science breakthrough that the Company has been pushing for since establishing the Dragon Silk line; this new transgenic was specifically engineered for high strength and significantly higher protein expression levels. This achievement marks a significant milestone in Kraig Labs’ mission to produce and commercialize eco-friendly materials that exceed the performance and strength of native spider silk. 

“This breakthrough has powerful ramifications that affect the core of how we develop future spider silk materials,” said COO Jon Rice.  “These newly confirmed transgenics mark a revolutionary advancement in capability of our spider silk materials. The new tools developed by Dr. Kane and our research team will allow us to target commercial markets that were not originally on our radar.”

Screening of these samples confirms that the gene edit was successful, validating the underlying protocols and genetic constructs.  Furthermore, western blot analysis, performed on the silk, confirms expression of this new and potentially much more powerful spider silk protein. These results open the door for the Company to deploy this new methodology towards a variety of tailored spider silk designs. Kraig Labs expects these new recombinant spider silk fiber lines will open up broader commercial opportunities and complement the Company’s existing Monster Silk™ and Dragon Silk™ technologies.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories submits Provisional Patent Applications on multiple Spider Silk Technologies

ANN ARBOR, Mich., – May 22, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has submitted five new provisional patent applications, for technologies related to its recombinant spider silk technologies.  These applications cover a broad range of technologies in the creation, screening, and production of new recombinant proteins.  These new applications expand beyond the Company’s publicly disclosed silkworm and silk technologies, to include advanced construction systems, methods, and non-native proteins. 

In November, of 2018, the Company retained Workman Nydegger as its Intellectual Property counsel and expects to utilize their expertise in prosecuting these, and all future, patent applications.

“Our R&D team is constantly looking for opportunities to strengthen our competitive potions, products, and processes. The recently submitted provisional patent applications cover key technologies and processes, invented by Dr. Kane and our team, as well as new applications that build upon our technologies,” said Kraig’s COO Jon Rice.  “These new technologies have the potential to significantly reduce future R&D costs and break open new markets for recombinant protein products, reaching far beyond silks and apparel.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories takes possession of factory in Vietnam

ANN ARBOR, Mich., – May 20, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its subsidiary Prodigy Textiles has taken possession of its factory in Vietnam.  The Company is now retrofitting the nearly 50,000 square foot facility to produce its game changing recombinant spider silk materials.   Remodeling efforts are expected to be minimal and completed quickly.  This facility was selected based on its optimal layout and existing infrastructure. 

“Our people on the ground, in Vietnam, are wasting no time getting this facility into operation.  We have outlined a very aggressive timeline for bringing the factory online and we are monitoring progress daily,” said Kraig’s COO Jon Rice.  “We are very pleased to see how quickly things are moving and look forward to completing the transition.  We expect to make delivery of the first production batch, of our recombinant spider silk thread, from this factory to one of our strategic market channel partners in the third or fourth quarter.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .

Kraig Biocraft Laboratories to be featured in upcoming documentary series on combating terrorism

Kraig Labs opens R&D headquarters to media for the first time

ANN ARBOR, Mich., – May 13, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its recombinant spider silk technology will be featured in a documentary focused on combating terrorism.  The Company opened the doors of its R&D headquarters, for the first time to the media, to host a French documentary film crew and provided them with access to the process of creating its incredible spider silk technologies.

Tougher and more flexible than competing materials, spider silk offers the promise of increased protection, comfort, and mobility in protective textile applications. In addition to this documentary, the Company has been covered by numerous media outlets, including the following T.EVO, Textile Evolution, article; https://www.tevonews.com/fibres-yarns-news/2026-polartec-figureheads-discuss-kraig-labs-silkworm-solution.

“Our team is incredibly proud of the work we do here and the impact that our Company is already making in these important markets,” said COO Jon Rice.  “It was a pleasure to be able to share the results of our efforts and to showcase this amazing technology along with its potential to disrupt the protective textile and related markets.”

The series is planned to air in the fall of 2019.  Although the footage was shot at Kraig Labs’ R&D headquarters in Michigan, the Company continues to focus its efforts on scaling up its production operations, through its subsidiary, Prodigy Textiles Ltd., in Asia.  By utilizing the existing global silk infrastructure and Kraig Labs’ engineered silkworm technology, the Company set to meet cost and volume metrics, previously thought to be impossible, in the commercialization of spider silk for these lifesaving applications in protective textiles.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

This entry was posted on by .